Li Hetong, Yang Dinglong, Hao Min, Liu Hongqi
Second Clinical Medical College, Shanxi Medical University, Taiyuan, China.
Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Front Genet. 2022 Aug 23;13:972664. doi: 10.3389/fgene.2022.972664. eCollection 2022.
T-cell immunoglobulin mucin 3 (TIM-3) has emerged as a promising immune checkpoint target in cancer therapy. However, the profile of the hepatitis A virus cellular receptor 2 () gene, encoding TIM-3 expression, is still obscure, along with its role in cancer immunity and prognosis. This study comprehensively analyzed expression patterns in pan-cancer and underlined its potential value for immune checkpoint inhibitor-based immunotherapy. Our results displayed that was differentially expressed and closely corresponded to survival status in pan-cancer. More importantly, the expression level was also significantly related to cancer immune infiltration, immune checkpoint genes, and immune marker genes. Enrichment analyses implicated -associated terms in cancer, including immunity, metabolism, and inflammation. Our study demonstrated that could participate in differing degrees of immune infiltration in tumorigenesis. The highlights of the pathway revealed that TIM-3 could function as both a biomarker and clinical target to improve the therapeutic efficacy of immunotherapy.
T细胞免疫球蛋白黏蛋白3（TIM-3）已成为癌症治疗中一个有前景的免疫检查点靶点。然而，编码TIM-3表达的甲型肝炎病毒细胞受体2（HAVCR2）基因的概况及其在癌症免疫和预后中的作用仍不清楚。本研究全面分析了HAVCR2在泛癌中的表达模式，并强调了其在基于免疫检查点抑制剂的免疫治疗中的潜在价值。我们的结果显示，HAVCR2在泛癌中差异表达，且与生存状态密切相关。更重要的是，HAVCR2表达水平也与癌症免疫浸润、免疫检查点基因和免疫标志物基因显著相关。富集分析表明HAVCR2相关术语涉及癌症中的免疫、代谢和炎症等方面。我们的研究表明，HAVCR2可在肿瘤发生过程中参与不同程度的免疫浸润。HAVCR2通路的亮点揭示，TIM-3既可以作为生物标志物，也可以作为临床靶点来提高免疫治疗的疗效。
